Sentence examples for baseline in frequencies of from inspiring English sources

At Week 56, after all patients were treated with onabotulinumtoxinA, there continued to be significant between-group differences favoring O/O vs P/O group for the following headache symptom measures: mean change from baseline in frequencies of headache days (-12.0 O/O, -11.1 P/O p=0.035), migraine days (-11.6 O/O, -10.7 P/O p=0.038), moderate/severe headache days (-11.0 O/O, -10.1 P/O p=0.042).

The Chi-square test will be performed to determine differences at baseline in frequencies of categorized variables between the groups.

The proportions of patients who experienced ≥50% reduction from baseline in frequencies of headache days, migraine days, moderate/severe headache days, headache episodes, migraine episodes, and total cumulative hours of headache on headache days were also determined.

At Week 24, change from baseline in frequency of acute headache medication intakes (secondary endpoint) was not statistically significant (p = 0.210) between groups, except for triptan intakes (p < 0.001), where the onabotulinumtoxinA-treated group was favored.

The primary efficacy end point was mean change from baseline in frequency of headache days for the 28-day period ending with week 12.

The proportions of patients with 75% decrease from baseline in frequency of headache days, headache episodes, migraine days, migraine episodes, moderate/severe headache days, and total cumulative hours of headache on headache days were analyzed.

In accordance with current guidelines of clinical trials in CM [24], the primary outcome measure was mean change from baseline in frequency of headache days (as recorded in the patient diary) for the 2 months-period ending with week 8. Baseline was defined as the 2 months-period before the first efficient injection.

The primary end point of the study was the change from baseline in frequency of weekly spontaneous bowel movements (SBMs) at week 1.

OnabotulinumtoxinA was significantly favored over placebo for the primary efficacy variable, mean change from baseline in frequency of headache days at all time points in the DBPC phase (Fig.  2).

The percent of patients with a ≥50% reduction from baseline in frequency of headache days was significantly greater for the onabotulinumtoxinA-only group at Week 56 (69.6% O/O, 62.8% P/O; P =  0.023).

By the end of the OL phase, approximately 70% of the early onabotulinumtoxinA-treated patients had a ≥50% reduction from baseline in frequency of headache days, and approximately 69% of the early onabotulinumtoxinA-treated patients had a ≥50% reduction in frequency of migraine days.